DK3971177T3 - Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer - Google Patents

Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer Download PDF

Info

Publication number: DK3971177T3
Authority: DK; Denmark
Prior art keywords: inhibitors; aminopyridine derivatives; selective alk; alk; selective
Prior art date: 2016-07-20

Application number

DK21202619.9T

Other languages

English (en)

Inventor

Jialiang Li

Luca Arista

Sreehari Babu

Jianwei Bian

Kai Cui

Michael Patrick Dillon

Rene Lattmann

Lv Liao

Rita Ramos

Nikolaus Johannes Stiefl

Thomas Ullrich

Peggy Usselmann

Xiaoyang Wang

Liladhar Murlidhar Waykole

Sven Weiler

Yubo Zhang

Yizong Zhou

Tingying Zhu

Dimitrios Lizos

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-20

Filing date

2017-07-18

Publication date

2024-07-15

2017-07-18 Application filed by Novartis Ag filed Critical Novartis Ag

2024-07-15 Application granted granted Critical

2024-07-15 Publication of DK3971177T3 publication Critical patent/DK3971177T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

DK21202619.9T 2016-07-20 2017-07-18 Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer DK3971177T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662364620P	2016-07-20	2016-07-20
EP17830463.0A EP3487851B1 (en)	2016-07-20	2017-07-18	Aminopyridine derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number	Publication Date
DK3971177T3 true DK3971177T3 (da)	2024-07-15

Family

ID=60991950

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK21202619.9T DK3971177T3 (da)	2016-07-20	2017-07-18	Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
DK17830463.0T DK3487851T3 (da)	2016-07-20	2017-07-18	Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK17830463.0T DK3487851T3 (da)	2016-07-20	2017-07-18	Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer

Country Status (26)

Country	Link
US (3)	US10710980B2 (da)
EP (3)	EP3487851B1 (da)
JP (4)	JP7030776B2 (da)
KR (7)	KR102719881B1 (da)
CN (2)	CN109641871B (da)
AR (1)	AR109108A1 (da)
AU (5)	AU2017298187B2 (da)
CA (1)	CA3030332A1 (da)
CY (1)	CY1124967T1 (da)
DK (2)	DK3971177T3 (da)
EA (2)	EA037520B1 (da)
ES (2)	ES2984746T3 (da)
FI (1)	FI3971177T3 (da)
HR (2)	HRP20241015T1 (da)
HU (2)	HUE057328T2 (da)
LT (2)	LT3971177T (da)
MX (2)	MX2019000837A (da)
PL (2)	PL3971177T3 (da)
PT (2)	PT3971177T (da)
RS (2)	RS62819B1 (da)
RU (1)	RU2747318C2 (da)
SI (2)	SI3971177T1 (da)
SM (2)	SMT202400335T1 (da)
TW (4)	TWI851226B (da)
UY (1)	UY37331A (da)
WO (1)	WO2018014829A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3971177T (lt) *	2016-07-20	2024-08-26	Novartis Ag	Aminopiridino dariniai ir jų panaudojimas kaip selektyvių alk-2 inhibitorių
CN115038443A (zh)	2019-11-22	2022-09-09	因西特公司	包含alk2抑制剂和jak2抑制剂的组合疗法
CN111170893B (zh) *	2020-01-19	2022-04-26	郑州依米花手性药物研究有限公司	Lefamulin的中间体化合物及其在Lefamulin制备中的应用
JP2023530316A (ja) *	2020-06-16	2023-07-14	インサイト・コーポレイション	貧血の治療のためのａｌｋ２阻害剤
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) *	2022-04-13	2023-10-19	杭州邦顺制药有限公司	Alk2激酶抑制剂

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5077290A (en)	1990-10-11	1991-12-31	Merck & Co., Inc.	Morpholine derivatives compositions and use
JP3362151B2 (ja)	1992-11-17	2003-01-07	ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ	アクチビンレセプター状キナーゼ活性を有するタンパク質をコードする単離核酸分子、及び、これを用いた発現ベクタ、組み換え細胞、単離タンパク質、単離抗体
TW530054B (en)	1997-09-24	2003-05-01	Duphar Int Res	New piperazine and piperidine compounds
SE0102439D0 (sv)	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
US6914058B2 (en) *	2002-01-18	2005-07-05	Dr. Reddy's Laboratories, Limited	Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
WO2004078163A2 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2003093297A2 (en)	2002-05-03	2003-11-13	Exelixis, Inc.	Protein kinase modulators and methods of use
AU2003249369A1 (en)	2002-06-21	2004-01-06	Cellular Genomics, Inc.	Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en)	2002-10-04	2004-04-08	Fortuna Haviv	Method of inhibiting angiogenesis
SE0203753D0 (sv)	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds
FR2850652B1 (fr) *	2003-01-31	2008-05-30	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2004230519A1 (en)	2003-04-11	2004-10-28	Sgx Pharmaceuticals, Inc.	Compound libraries and methods for drug discovery
EP1758862A1 (en)	2004-05-27	2007-03-07	Pfizer Limited	Aminopyridine derivatives as selective dopamine d3 agonists
SA05260265A (ar)	2004-08-30	2005-12-03	استرازينيكا ايه بي	مركبات جديدة
KR20080004584A (ko)	2005-04-08	2008-01-09	에자이 알앤드디 매니지먼트 가부시키가이샤	불수의 운동 치료제
WO2007011760A2 (en)	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
GB0517175D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AR059037A1 (es) *	2006-01-17	2008-03-12	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
US8895711B2 (en)	2006-04-18	2014-11-25	The Trustees Of The University Of Pennsylvania	Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
WO2008002671A2 (en)	2006-06-29	2008-01-03	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors
WO2008030611A2 (en)	2006-09-05	2008-03-13	Medarex, Inc.	Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
WO2008033408A2 (en)	2006-09-12	2008-03-20	The General Hospital Corporation	Methods for identifying compounds that modulate cell signaling and methods employing such compounds
UA97813C2 (uk) *	2006-12-05	2012-03-26	Янссен Фармацевтика Н.В.	Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
US8507501B2 (en)	2008-03-13	2013-08-13	The Brigham And Women's Hospital, Inc.	Inhibitors of the BMP signaling pathway
CN102203074A (zh)	2008-06-20	2011-09-28	麦它波莱克斯股份有限公司	芳基gpr119激动剂及其用途
BR112013003587B1 (pt)	2010-08-20	2022-11-08	Wyeth Llc	Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada
AU2011340167A1 (en)	2010-12-06	2013-07-18	Piramal Enterprises Limited	Substituted imidazoquinoline derivatives
WO2012087938A1 (en)	2010-12-20	2012-06-28	Glaxosmithkline Llc	Quinazolinone derivatives as antiviral agents
US8987271B2 (en)	2010-12-22	2015-03-24	Eutropics Pharmaceuticals, Inc.	2,2′-biphenazine compounds and methods useful for treating disease
SG194105A1 (en)	2011-05-23	2013-11-29	Merck Patent Gmbh	Pyridine-and pyrazine derivatives
EP3567029A1 (en)	2011-09-09	2019-11-13	Lantheus Medical Imaging, Inc.	Compositions, methods, and systems for the synthesis and use of imaging agents
CA2886187C (en)	2012-09-28	2020-04-14	Vanderbilt University	Fused heterocyclic compounds as selective bmp inhibitors
US20160115167A1 (en) *	2013-03-04	2016-04-28	The Brigham And Women's Hospital, Inc.	Bmp inhibitors and methods of use thereof
CA2905993C (en)	2013-03-14	2022-12-06	Tolero Pharmaceuticals, Inc.	Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US9682983B2 (en)	2013-03-14	2017-06-20	The Brigham And Women's Hospital, Inc.	BMP inhibitors and methods of use thereof
MX2016005054A (es)	2013-10-21	2016-07-19	Merck Patent Gmbh	Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos.
JP6601687B2 (ja)	2014-03-31	2019-11-06	大日本住友製薬株式会社	進行性骨化性線維異形成症の予防剤及び治療剤
JP6771469B2 (ja)	2015-01-20	2020-10-21	ベーリンガーインゲルハイムアニマルヘルスユーエスエイインコーポレイテッド	駆虫性化合物、組成物及びこれらの使用方法
LT3971177T (lt) *	2016-07-20	2024-08-26	Novartis Ag	Aminopiridino dariniai ir jų panaudojimas kaip selektyvių alk-2 inhibitorių
WO2018017635A1 (en)	2016-07-20	2018-01-25	Cavendish Kinetics, Inc	Method for tuning an antenna with a dvc
WO2018106820A1 (en)	2016-12-07	2018-06-14	Kura Oncology, Inc.	Methods of promoting beta cell proliferation

2017
- 2017-07-18 LT LTEP21202619.9T patent/LT3971177T/lt unknown
- 2017-07-18 SM SM20240335T patent/SMT202400335T1/it unknown
- 2017-07-18 HU HUE17830463A patent/HUE057328T2/hu unknown
- 2017-07-18 HR HRP20241015TT patent/HRP20241015T1/hr unknown
- 2017-07-18 PL PL21202619.9T patent/PL3971177T3/pl unknown
- 2017-07-18 KR KR1020247016068A patent/KR102719881B1/ko active Active
- 2017-07-18 EA EA201990343A patent/EA037520B1/ru unknown
- 2017-07-18 LT LTEPPCT/CN2017/093385T patent/LT3487851T/lt unknown
- 2017-07-18 KR KR1020217022916A patent/KR102359707B1/ko active Active
- 2017-07-18 CN CN201780044640.4A patent/CN109641871B/zh active Active
- 2017-07-18 CN CN202111145806.6A patent/CN114014844B/zh active Active
- 2017-07-18 DK DK21202619.9T patent/DK3971177T3/da active
- 2017-07-18 TW TW112118991A patent/TWI851226B/zh active
- 2017-07-18 SI SI201731538T patent/SI3971177T1/sl unknown
- 2017-07-18 TW TW110101592A patent/TWI755255B/zh active
- 2017-07-18 SM SM20210723T patent/SMT202100723T1/it unknown
- 2017-07-18 ES ES21202619T patent/ES2984746T3/es active Active
- 2017-07-18 KR KR1020227003660A patent/KR102454129B1/ko active Active
- 2017-07-18 PL PL17830463T patent/PL3487851T3/pl unknown
- 2017-07-18 KR KR1020227034980A patent/KR102559539B1/ko active Active
- 2017-07-18 HU HUE21202619A patent/HUE067992T2/hu unknown
- 2017-07-18 PT PT212026199T patent/PT3971177T/pt unknown
- 2017-07-18 DK DK17830463.0T patent/DK3487851T3/da active
- 2017-07-18 HR HRP20211868TT patent/HRP20211868T1/hr unknown
- 2017-07-18 RS RS20211582A patent/RS62819B1/sr unknown
- 2017-07-18 KR KR1020247034434A patent/KR20240155367A/ko active Pending
- 2017-07-18 US US16/318,250 patent/US10710980B2/en active Active
- 2017-07-18 TW TW111103316A patent/TWI806385B/zh active
- 2017-07-18 TW TW106123900A patent/TWI712598B/zh active
- 2017-07-18 EP EP17830463.0A patent/EP3487851B1/en active Active
- 2017-07-18 EP EP21202619.9A patent/EP3971177B1/en active Active
- 2017-07-18 RU RU2019104609A patent/RU2747318C2/ru active
- 2017-07-18 KR KR1020237024969A patent/KR102667331B1/ko active Active
- 2017-07-18 KR KR1020197004529A patent/KR102281550B1/ko active Active
- 2017-07-18 JP JP2019502675A patent/JP7030776B2/ja active Active
- 2017-07-18 EA EA202190285A patent/EA202190285A1/ru unknown
- 2017-07-18 CA CA3030332A patent/CA3030332A1/en active Pending
- 2017-07-18 RS RS20241041A patent/RS66041B1/sr unknown
- 2017-07-18 PT PT178304630T patent/PT3487851T/pt unknown
- 2017-07-18 ES ES17830463T patent/ES2902521T3/es active Active
- 2017-07-18 SI SI201731040T patent/SI3487851T1/sl unknown
- 2017-07-18 MX MX2019000837A patent/MX2019000837A/es unknown
- 2017-07-18 WO PCT/CN2017/093385 patent/WO2018014829A1/en unknown
- 2017-07-18 EP EP24183394.6A patent/EP4442317A3/en active Pending
- 2017-07-18 AU AU2017298187A patent/AU2017298187B2/en active Active
- 2017-07-18 FI FIEP21202619.9T patent/FI3971177T3/fi active
- 2017-07-19 UY UY0001037331A patent/UY37331A/es not_active Application Discontinuation
- 2017-07-20 AR ARP170102033A patent/AR109108A1/es unknown
2019
- 2019-01-18 MX MX2021014852A patent/MX2021014852A/es unknown
- 2019-10-10 AU AU2019246857A patent/AU2019246857B2/en active Active
2020
- 2020-05-27 US US16/884,666 patent/US10947218B2/en active Active
2021
- 2021-02-08 US US17/170,690 patent/US20210155606A1/en active Pending
- 2021-03-04 AU AU2021201424A patent/AU2021201424C1/en active Active
- 2021-12-29 CY CY20211101137T patent/CY1124967T1/el unknown
2022
- 2022-02-22 JP JP2022025894A patent/JP7253086B2/ja active Active
2023
- 2023-01-19 AU AU2023200265A patent/AU2023200265B2/en active Active
- 2023-03-24 JP JP2023048083A patent/JP7584553B2/ja active Active
2024
- 2024-07-24 AU AU2024205058A patent/AU2024205058A1/en active Pending
- 2024-11-05 JP JP2024193634A patent/JP2025032086A/ja active Pending

Also Published As

Publication number	Publication date
KR20240074904A (ko)	2024-05-28
KR20240155367A (ko)	2024-10-28
EP4442317A2 (en)	2024-10-09
PL3487851T3 (pl)	2022-04-11
CA3030332A1 (en)	2018-01-25
US10947218B2 (en)	2021-03-16
AR109108A1 (es)	2018-10-31
EP3487851B1 (en)	2021-10-20
HUE057328T2 (hu)	2022-05-28
EP4442317A3 (en)	2025-01-01
SI3971177T1 (sl)	2024-10-30
JP2022078137A (ja)	2022-05-24
AU2023200265B2 (en)	2024-08-15
HRP20241015T1 (hr)	2024-11-08
FI3971177T3 (fi)	2024-07-30
CN114014844B (zh)	2024-10-01
US20210155606A1 (en)	2021-05-27
HUE067992T2 (hu)	2024-12-28
TWI755255B (zh)	2022-02-11
KR20220021023A (ko)	2022-02-21
BR112019000941A2 (pt)	2019-04-30
MX2019000837A (es)	2019-07-04
KR102667331B1 (ko)	2024-05-21
RS66041B1 (sr)	2024-11-29
EA202190285A1 (ru)	2021-08-31
EA201990343A1 (ru)	2019-06-28
JP2019521167A (ja)	2019-07-25
PL3971177T3 (pl)	2024-10-28
TW202220969A (zh)	2022-06-01
AU2017298187B2 (en)	2019-11-14
AU2021201424C1 (en)	2023-02-02
KR102559539B1 (ko)	2023-07-26
AU2023200265A1 (en)	2023-02-16
EA037520B1 (ru)	2021-04-07
TWI806385B (zh)	2023-06-21
KR20230117248A (ko)	2023-08-07
KR102454129B1 (ko)	2022-10-14
JP7584553B2 (ja)	2024-11-15
KR102281550B1 (ko)	2021-07-27
SMT202400335T1 (it)	2024-09-16
JP2025032086A (ja)	2025-03-11
RU2019104609A3 (da)	2020-09-30
SI3487851T1 (sl)	2022-03-31
SMT202100723T1 (it)	2022-01-10
PT3971177T (pt)	2024-07-30
JP7030776B2 (ja)	2022-03-07
TWI712598B (zh)	2020-12-11
RS62819B1 (sr)	2022-02-28
KR20210094138A (ko)	2021-07-28
DK3487851T3 (da)	2021-12-20
JP2023089012A (ja)	2023-06-27
KR102719881B1 (ko)	2024-10-23
TW202336011A (zh)	2023-09-16
RU2021111037A3 (da)	2022-02-10
US10710980B2 (en)	2020-07-14
AU2024205058A1 (en)	2024-08-15
UY37331A (es)	2018-02-28
MX2021014852A (es)	2022-01-18
US20200299265A1 (en)	2020-09-24
KR102359707B1 (ko)	2022-02-09
EP3971177A1 (en)	2022-03-23
JP7253086B2 (ja)	2023-04-05
WO2018014829A1 (en)	2018-01-25
KR20220143770A (ko)	2022-10-25
LT3487851T (lt)	2021-12-27
RU2019104609A (ru)	2020-08-20
TW202134228A (zh)	2021-09-16
ES2902521T3 (es)	2022-03-28
AU2017298187A1 (en)	2018-12-20
LT3971177T (lt)	2024-08-26
AU2019246857B2 (en)	2020-12-24
CY1124967T1 (el)	2023-01-05
EP3487851A4 (en)	2019-12-25
TWI851226B (zh)	2024-08-01
PT3487851T (pt)	2022-01-07
ES2984746T3 (es)	2024-10-30
KR20190026917A (ko)	2019-03-13
AU2021201424B2 (en)	2022-10-20
EP3971177B1 (en)	2024-06-26
US20190161474A1 (en)	2019-05-30
RU2021111037A (ru)	2021-05-13
RU2747318C2 (ru)	2021-05-04
AU2019246857A1 (en)	2019-10-31
CN114014844A (zh)	2022-02-08
AU2021201424A1 (en)	2021-03-25
CN109641871A (zh)	2019-04-16
HRP20211868T1 (hr)	2022-03-04
CN109641871B (zh)	2021-10-22
TW201805277A (zh)	2018-02-16
EP3487851A1 (en)	2019-05-29

Publication	Publication Date	Title
DK3331894T3 (da)	2021-03-22	Nicotinamidmononukleotidderivater og anvendelser deraf
DK3328849T3 (da)	2020-09-21	1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3452463T3 (da)	2021-04-26	Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3307707T3 (da)	2020-12-21	Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3984996T3 (da)	2024-10-21	Aminopyridin-SSAO-inhibitorer
DK3277681T3 (da)	2019-07-29	Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3149001T3 (da)	2019-07-22	Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3786160T3 (da)	2022-08-22	Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3557998T3 (da)	2023-11-20	Sammensætninger, kompositioner og anvendelsesmetoder
DK3559000T3 (da)	2022-06-07	Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3971177T3 (da)	2024-07-15	Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
DK3214079T3 (da)	2020-09-28	Seks-leddede benzodiazepinderivater som dpp-4-inhibitorer og hvordan de bruges
DK3347356T3 (da)	2021-04-26	Tricyclic forbundet pyridin-2-one-derivater og deres anvendelse som brd4-hæmmere
DK3398598T3 (da)	2022-07-11	Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3110837T3 (da)	2019-09-16	Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
DK3280405T3 (da)	2021-09-06	Inhibitorer og anvendelser deraf
DK3455216T3 (da)	2021-01-18	Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer
DK3386956T3 (da)	2021-10-11	Fumagillolderivater og polymorfer deraf
DK3277682T3 (da)	2019-07-29	6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere
IL274722A (en)	2020-07-30	History of pyridinones and their use as selective inhibitors of ALK-2
DK3091005T3 (da)	2020-12-21	1,2-naphthoquinonderivat og fremgangsmåde til fremstilling deraf
DK3724196T3 (da)	2023-01-16	Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
DK3362450T3 (da)	2020-09-14	N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose
DK3712162T3 (da)	2022-09-19	Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf